Sometimes the market moves for really obvious reasons. Vanda Pharmaceuticals Inc. (VNDA) shares rocketed up 17.5% to $8.26 in premarket trading Wednesday, and there's no mystery why: The U.S. Food and Drug Administration just approved NEREUS (tradipitant), an oral neurokinin-1 receptor antagonist for preventing motion-induced vomiting in adults. If you're wondering what that means in plain English, it's a pill that helps adults not throw up when they're on boats, planes, or carnival rides. That's a real market, and now Vanda has FDA approval to serve it.

But Vanda wasn't alone in making big moves before the opening bell. Here's what else was happening in the premarket session.

The Big Gainers

Aimei Health Technology Co Ltd (AFJK) was the runaway winner, surging 61.6% to $133.00 in premarket trading. This came after the stock already jumped 89% on Tuesday, so we're looking at some serious momentum here.

Anghami Inc (ANGH) climbed 49.1% to $3.46 following the release of the company's six-month results. The Middle Eastern music streaming platform clearly had something in those numbers that investors liked.

Oriental Rise Holdings Ltd (ORIS) rose 42.6% to $1.74 after announcing a nonbinding letter of intent to acquire a controlling stake in Hubei Daguan Tea Industry Group Co. Ltd., a leading tea producer in Yingshan County, Hubei Province. Letters of intent aren't binding contracts, but the market is betting this deal happens.

Northann Corp (NCL) bounced back 39.7% to $0.27 after dropping 15% on Tuesday. Classic volatility in the penny stock space.

Inspire Veterinary Partners Inc (IVP) gained 35.4% to $0.068, extending Tuesday's 18% climb. The veterinary services company continues its recovery trajectory.

iSpecimen Inc (ISPC) rose 29.1% to $0.38 after announcing a $5.5 million private placement with accredited investors. The biospecimen marketplace operator is raising cash, and investors seem fine with the dilution for now.

Direct Digital Holdings Inc (DRCT) gained 28.4% to $0.077, building on Tuesday's 12% jump. The digital advertising company has been on a bit of a tear.

A SPAC III Acquisition Corp (ASPC) rose 25% to $34.84 in premarket trading. No specific news here, but SPACs can move on merger speculation or arbitrage activity.

LI Bang International Corporation Inc (LBGJ) gained 24.5% to $0.66 after declining around 13% on Tuesday. Another bounce-back story in the small-cap space.

The Decliners

Profusa Inc (PFSA) fell 14.5% to $0.10 despite announcing debt restructuring and reduced potential shareholder dilution. Sometimes good news doesn't translate to upward momentum, especially if traders were hoping for something more dramatic or if there was speculative buying that's now unwinding.

ATIF Holdings Ltd (ZBAI) dropped 12.1% to $5.21 after filing for a mixed shelf offering of up to $500 million. That's a massive potential dilution hanging over current shareholders, and the market is pricing in that risk immediately.

Fitell Corp (FTEL) fell 12.1% to $0.60 in premarket trading with no specific news driving the decline.

Brenmiller Energy Ltd (BNRG) dipped 11.8% to $0.54, extending Tuesday's 24% decline. The thermal energy storage company is in a serious downdraft.

Akari Therapeutics PLC (AKTX) fell 11.1% to $0.24 with no catalyst provided for the move.

Intercont (Cayman) Ltd (NCT) declined 8.7% to $0.20 after dipping over 4% on Tuesday. The selling pressure continues for the offshore company.

Antelope Enterprise Holdings Ltd (AEHL) gave back 8.3% to $2.00 after gaining 92% on Tuesday. When you rocket up that much in a single session, some profit-taking is practically inevitable.

Milestone Scientific Inc (MLSS) fell 8.6% to $0.25, continuing Tuesday's decline of over 5%. The dental and medical technology company is trending downward.

Jefferson Capital Inc (JCAP) shares dipped 7.2% to $21.08 in premarket trading without specific news.

Cybin Inc (CYBN) tumbled 6.6% to $8.00 after launching a $100 million at-the-market equity program with Cantor Fitzgerald. ATM offerings let companies sell shares gradually into the market, but they still represent dilution, and investors are reacting to that prospect.

The premarket session is always a wild ride, with stocks moving on everything from FDA approvals to shelf registrations to absolutely nothing at all. By the time the opening bell rings, some of these moves will stick, and others will fade away. That's just how markets work.